Sun Pharma anticipates revenue growth for fiscal year 26, building on an 8% increase in fiscal year 25. However, increased spending on marketing specialty products may impact profitability. Net profit declined in the March quarter due to higher taxes. The company plans to launch new drugs like Leqselvi and Unloxcyt.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets